Table 9, Summary of included studies. Comparison 8. Augmenting with self-help and switching to SSRI versus switching to SSRI-only - Further-line treatment

Warning: The NCBI web site requires JavaScript to function. more...

Study	Population	Intervention	Comparison	Details of inadequate response/treatment resistance	Comments
Mantani 2017 RCT Japan	N=164 Mean age (years): 40.9 Gender (% female): 53 Ethnicity (% BME): NR Baseline severity: PHQ-9 13.2 (less severe)	Computerised CBT (CCBT) + switch to escitalopram 5-10 mg/day or sertraline 25-100 mg/day Intensity: 8 sessions	Switch to escitalopram 5-10 mg/day or sertraline 25-100 mg/day	Inadequate response (BDI-II≥10) after taking 1 or more antidepressants at an adequate dosage for at least 4 weeks	Treatment length (weeks): 9 Outcomes: Depression symptomatology endpoint Depression symptomatology change score Remission Response Discontinuation due to any reason

Study

Population

Intervention

Comparison

Details of inadequate response/treatment resistance

Comments

RCT

Japan

N=164

Mean age (years): 40.9

Gender (% female): 53

Ethnicity (% BME): NR

Baseline severity: PHQ-9 13.2 (less severe)

Computerised CBT (CCBT) + switch to escitalopram 5-10 mg/day or sertraline 25-100 mg/day

Intensity: 8 sessions

Switch to escitalopram 5-10 mg/day or sertraline 25-100 mg/day

Inadequate response (BDI-II≥10) after taking 1 or more antidepressants at an adequate dosage for at least 4 weeks

Treatment length (weeks): 9

Outcomes:

: BDI-II: Beck depression inventory; BME: black and minority ethnic; NR: not reported; PHQ-9: patient health questionnaire-9 item; RCT: randomised controlled trial; SSRI: selective serotonin reuptake inhibitors

Further-line treatment: Depression in adults: Evidence review D.

NICE Guideline, No. 222.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.